Vitreomacular traction is what happens when the gel inside the eye doesn’t let go of the macula completely. The pull it creates is gradual, often subtle at first, and occasionally resolves on its own. When it doesn’t, the consequences for central vision can be significant.
As the eye ages, the vitreous gel that fills most of the eye slowly shrinks and liquefies. In most people this leads to a clean separation from the retina – the posterior vitreous detachment that causes floaters and flashes. In some, the vitreous remains stuck to the macula, the central part of the retina responsible for reading and detailed vision. This persistent attachment creates traction – a mechanical pull on delicate retinal tissue. Vitreomacular traction, or VMT, describes this specific scenario: an incomplete posterior vitreous detachment with a focal adhesion at the macula that is distorting or threatening to damage it.
What You Need to Know About Vitreomacular Traction
- VMT occurs when the vitreous gel remains attached to the macula during an otherwise incomplete posterior vitreous detachment
- The traction can distort macular architecture, cause visual symptoms ranging from mild metamorphopsia to significant central vision loss, and potentially lead to macular hole formation
- OCT is the essential diagnostic tool – it reveals the precise anatomy of the vitreoretinal interface in a way that was impossible before its development
- Spontaneous release of the vitreous adhesion occurs in around 25–40% of cases, resolving the traction without treatment
- For cases that need intervention, options include an injection of ocriplasmin (pharmacological vitreolysis) and vitrectomy surgery
- VMT exists on a spectrum with epiretinal membrane and macular hole – understanding where a given patient sits on that spectrum guides treatment decisions
How VMT Develops
The posterior vitreous detachment process doesn’t always go smoothly. In the vast majority of people it separates cleanly, the vitreous collapsing away from the retina and leaving behind a ring-shaped floater. But in some eyes – particularly those with stronger adhesion at the macula – the separation stalls. The vitreous peels away from the peripheral retina but remains stuck centrally, tethered to the fovea or the small area immediately surrounding it.
That tethered attachment doesn’t just sit there passively. The vitreous continues to contract, pulling the foveal tissue anteriorly – toward the centre of the eye. This mechanical stress is what defines VMT. The consequences depend on the size and strength of the adhesion, the anatomy of the individual eye, and time.
The VMT spectrum
VMT doesn’t exist in isolation. It sits at a point on a broader spectrum of vitreoretinal interface disorders:
- Vitreous attached to the macula but no retinal distortion
- Asymptomatic or nearly so
- May progress to VMT or resolve spontaneously
- Observation is appropriate – no treatment needed
- Identified on OCT as incidental finding
- Attachment with demonstrable retinal distortion on OCT
- Symptoms: metamorphopsia, reduced acuity, micropsia
- Risk of progression to macular hole
- Treatment decision depends on symptoms and rate of progression
- Spontaneous resolution possible but less likely than VMA
At the more severe end, VMT can lead to a full-thickness macular hole if the traction tears through the foveal tissue. Epiretinal membrane – a sheet of fibrous tissue growing on the retinal surface – frequently develops alongside VMT, compounding the distortion.
Symptoms
VMT symptoms stem directly from distortion of the fovea, the tiny region responsible for the sharpest central vision. The most characteristic symptom is metamorphopsia – straight lines appearing wavy or bent. Reading becomes difficult when words look distorted even with correct spectacle correction. A central blurred or grey patch may develop. Objects can appear smaller than they should (micropsia). Some patients describe an overall dimming or reduced contrast in the affected eye.
Mild cases can be surprisingly easy to miss, particularly if the fellow eye compensates. Many patients first notice symptoms when covering one eye for an unrelated reason and discovering the difference. Others are identified during routine OCT scanning done for other indications.
Diagnosis
OCT has completely changed how this condition is diagnosed and managed. Before OCT became widespread, VMT was frequently missed or diagnosed late. A good-quality OCT scan of the macula shows the vitreoretinal interface directly, revealing the adhesion, the degree of retinal distortion, and any associated changes like cyst formation or epiretinal membrane. The foveal contour, normally a smooth concave depression, becomes distorted in proportion to the traction applied.
The ophthalmologist will also assess visual acuity, perform an Amsler grid test to characterise the metamorphopsia, and look for associated findings on dilated fundus examination. Repeat OCT over weeks to months is used to monitor for spontaneous resolution or progression – this serial imaging is what guides the timing of intervention.
Treatment
Watch and wait – appropriate for many patients
Because spontaneous resolution occurs in a meaningful proportion of cases, initial observation is reasonable for patients with mild symptoms and preserved visual acuity. Serial OCT monitoring – typically every 2–3 months – tracks whether the adhesion is changing. If vision remains good and there’s no sign of worsening distortion or threatened macular hole formation, continued monitoring is a valid and common management path.
Pharmacological vitreolysis – a non-surgical option
Ocriplasmin (Jetrea) is an enzyme injected into the vitreous that cleaves proteins at the vitreoretinal interface, promoting separation of the vitreous from the retina. It works best in eyes with a focal, small adhesion without a concurrent epiretinal membrane. Success rates for achieving full VMT release are moderate – around 25–40% in suitable patients – but for those it works in, it avoids surgery entirely. Side effects include transient vision changes and, rarely, more significant complications. Patient selection matters considerably.
The definitive treatment for significant VMT
Pars plana vitrectomy removes the vitreous gel and directly releases the traction by peeling the posterior vitreous cortex from the macular surface. For patients with persistent VMT, worsening symptoms, or development of a macular hole, vitrectomy offers the highest rate of anatomical and visual success. The surgery is performed under local anaesthesia, usually as a day case, by a retinal surgeon. Recovery depends on what additional steps are needed – if a macular hole has already formed, a gas bubble and face-down positioning will be required.
VMT, Macular Hole, and Epiretinal Membrane
These three conditions overlap considerably and are frequently discussed together. VMT is the mechanical process; the others are its potential consequences.
An epiretinal membrane is a thin fibrous sheet growing on the retinal surface, often triggered by the same incomplete PVD process. It causes its own distortion and frequently coexists with VMT, making the overall picture more complex and reducing the likely response to ocriplasmin.
A macular hole is the most feared complication of untreated VMT. When the tractional force tears through the full thickness of the foveal tissue, a hole forms. This causes a distinct dense central scotoma – a black or grey spot in the centre of vision – rather than the waviness of VMT alone. Macular holes are surgically repairable in most cases when caught in time, but they represent a step-down in outcome compared to treating VMT before it progresses that far.
See Your Ophthalmologist Promptly If You Notice
- A sudden increase in distortion or a new central blind spot – this may indicate a macular hole has formed
- Rapid worsening of reading vision over days rather than weeks
- New floaters or flashes alongside the metamorphopsia
- Any change in vision in the other eye, which so far may have been compensating without you realising
VMT is not a condition that announces emergencies loudly, but macular hole formation can change quite quickly. If the pattern of your symptoms shifts, don’t wait for a scheduled follow-up appointment.
Frequently Asked Questions About Vitreomacular Traction
-
Can VMT resolve without any treatment?
Yes, in a meaningful proportion of patients. Spontaneous release of the vitreous adhesion occurs in roughly 25–40% of cases, typically within the first year of diagnosis. This is one reason why observation is a legitimate first-line approach, particularly for mild cases. Regular OCT monitoring allows the clinician to act if the situation worsens rather than resolving.
-
How quickly does VMT progress to a macular hole?
It varies considerably. Some patients have stable VMT for years without forming a hole; others progress within months. Size of the adhesion, severity of the distortion, and associated features on OCT help predict progression risk, but there’s genuine individual variability. This is why monitoring frequency is tailored to each patient rather than fixed.
-
Is the ocriplasmin injection painful?
The injection is performed under topical anaesthesia – numbing drops – so the procedure itself is not painful. A brief pressure sensation is common. In the days following, some patients experience transient visual changes including reduced acuity or colour changes, which usually resolve. These temporary effects can be disconcerting if you’re not warned about them in advance. Ask your surgeon specifically what to expect.
-
Will my vision return to normal after vitrectomy?
Most patients improve, but the extent depends on how much damage the traction has already caused to the foveal tissue. Eyes treated early, before significant structural damage, tend to do best. Eyes with longstanding VMT or associated macular hole may achieve improvement but not complete restoration. The goal is stopping further deterioration and recovering as much vision as possible.
-
Does having VMT in one eye mean the other eye is at risk?
Not directly – VMT results from an individual eye’s PVD process rather than a systemic condition. However, since both eyes will eventually go through posterior vitreous detachment, the other eye is worth monitoring, particularly if it develops symptoms of PVD. Most people with VMT in one eye do not develop it in the other.
The American Academy of Ophthalmology’s macular hole page covers the closely related condition that VMT can lead to. For a detailed review of the vitreoretinal interface and the spectrum of disorders including VMT, this published review in the Journal of Ophthalmology provides a thorough clinical overview. Further information on related retinal conditions is available through our retina subspecialty section.